Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Rare Inherited Anemias
NCT07331818Phase 2Not yet recruiting
- Sponsor
- EuroBloodNet Association
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of luspatercept in hereditary anemia, sideroblastic anemia (SA), congenital dyserythropoietic anemia (CDA), Diamond-Blackfan anemia (DBA), sponsored by EuroBloodNet Association. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
hereditary anemiasideroblastic anemia (SA)congenital dyserythropoietic anemia (CDA)Diamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT07331818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331818.